Literature DB >> 17973031

Intratemporal Grafting of the Facial Nerve following Lateral Skull Base Tumor Resection.

John P Leonetti1, Douglas E Anderson, Sam J Marzo, Thomas C Origitano, Guy J Petruzzelli.   

Abstract

UNLABELLED: Intratemporal skull base tumors may invade the facial nerve in the horizontal (tympanic) or descending (vertical) segments, while parotid malignancies typically infiltrate the facial nerve at the stylomastoid foramen. This article will describe our results following intratemporal facial nerve grafting in 44 patients.
METHODS: This was a retrospective analysis of 44 patients requiring intratemporal facial nerve repair following lateral skull base tumor resection at our tertiary care, academic medical center.
RESULTS: Tumor histology included 17 parotid cancers, 13 temporal bone malignancies, 9 glomus tumors, 3 facial neuromas, and 2 endolymphatic sac tumors. The greater auricular nerve was used in 25 patients and the sural nerve was used in 19 cases. Forty patients were available for facial function assessment at 2 years. Using the House-Brackmann (H-B) recovery scale, the breakdown of patients by facial function was as follows: Grade I, 0 patients; Grade II, 4 patients; Grade III, 29 patients; Grade IV, 4 patients; Grade V, 3 patients; and Grade VI, 0 patients.
CONCLUSIONS: Facial paralysis may occur from intrinsic or external lateral skull base invasion of the facial nerve. Intratemporal interposition grafting resulted in favorable facial function (H-B II or III) in 33 of the 40 (82.5%) patients at the 2-year assessment.

Entities:  

Year:  2007        PMID: 17973031      PMCID: PMC1888740          DOI: 10.1055/s-2007-977464

Source DB:  PubMed          Journal:  Skull Base        ISSN: 1531-5010


  13 in total

1.  Early facial reanimation following radical parotid and temporal bone tumor resections.

Authors:  S M Sobol; M May; S Mester
Journal:  Am J Surg       Date:  1990-10       Impact factor: 2.565

2.  Facial nerve repair by interposition nerve graft: results in 22 patients.

Authors:  E Stephanian; L N Sekhar; I P Janecka; B Hirsch
Journal:  Neurosurgery       Date:  1992-07       Impact factor: 4.654

3.  Carcinoma of major salivary glands. Recent trends.

Authors:  R H Spiro; J Armstrong; L Harrison; N L Geller; S Y Lin; E W Strong
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1989-03

4.  Parotid masses: evaluation, analysis, and current management.

Authors:  M N Byrne; J G Spector
Journal:  Laryngoscope       Date:  1988-01       Impact factor: 3.325

Review 5.  Electroneurography and intraoperative facial monitoring in contemporary neurotology.

Authors:  J M Kartush
Journal:  Otolaryngol Head Neck Surg       Date:  1989-10       Impact factor: 3.497

6.  Facial nerve grading system.

Authors:  J W House; D E Brackmann
Journal:  Otolaryngol Head Neck Surg       Date:  1985-04       Impact factor: 3.497

7.  Facial nerve function after petrosectomy.

Authors:  R Häusler; M Caversaccio; P Zbären
Journal:  Laryngoscope       Date:  1999-07       Impact factor: 3.325

8.  Malignant parotid tumors in 110 consecutive patients: treatment results and prognosis.

Authors:  D Pedersen; J Overgaard; H Søgaard; O Elbrønd; M Overgaard
Journal:  Laryngoscope       Date:  1992-09       Impact factor: 3.325

9.  Facial nerve management in cranial base surgery.

Authors:  I P Janecka; L N Sekhar; C N Sen
Journal:  Laryngoscope       Date:  1993-03       Impact factor: 3.325

10.  Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy.

Authors:  J G Armstrong; L B Harrison; R H Spiro; D E Fass; E W Strong; Z Y Fuks
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1990-03
View more
  1 in total

Review 1.  Outcomes and prognostic factors of facial nerve repair: a retrospective comparative study of 31 patients and literature review.

Authors:  Fabienne Carré; Rémi Hervochon; Ghizlene Lahlou; Diane Lastennet; Peggy Gatignol; Daniele Bernardeschi; Georges Lamas; Frédéric Tankéré
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-08-17       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.